期刊文献+

硼替佐米为主方案治疗多发性骨髓瘤患者的临床研究 被引量:12

原文传递
导出
摘要 目前多发性骨髓瘤(MM)常用的化疗方案有MP(马法兰+泼尼松)、VAD(长春新碱、阿霉素及地塞米松)等,但上述方案治疗起效慢,完全缓解率低,反应持续时间短[1],临床疗效不尽人意.2009年美国国家综合癌症网(National Comprehensive Cancer Network,NCCN)MM诊治指南中将硼替佐米推荐为MM的一线用药[2].近年来多项研究发现其在MM的治疗中取得了较好的疗效[3-4].为了进一步观察硼替佐米治疗MM患者的疗效,我们将39例MM患者治疗的结果报道如下.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2011年第4期265-267,共3页 Chinese Journal of Hematology
  • 相关文献

参考文献9

  • 1Palumbo A,Bringhen S,Caravita T,et al.Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma:randomised controlled trial.Lancet,2006,367:825-831. 被引量:1
  • 2National Comprehensive Cancer Network (NCCN).NCCN Clinical Practice Guidelines in Oncology MM (2009 V3).http://www.nccn.org. 被引量:1
  • 3Oakervee HE,Popat R,Curry N,et al.PAD combination therapy (PS-341/bortezomib,doxorbicin and dexamethasone) for previously untreated patients with multiple myeloma.Br J Haematol,2005,129:755-762. 被引量:1
  • 4Richardson PG,Barlogie B,Berenson J,et al.Extended follow-up of a phase Ⅱ trial in relapsed,refractory multiple myeloma:final time-to-event results from the SUMMIT trial.Cancer,2006,106:1316-1319. 被引量:1
  • 5张之南,沈悌主编..血液病诊断及疗效标准 第3版[M].北京:科学出版社,2007:271.
  • 6Bladé J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation.Myeloma Committee of the EBMT European Group for Blood and Marrow Transplant.Br J Haematol,1998,102:1115-1231. 被引量:1
  • 7Anderson KC.Multiple myeloma:how far have we come? Mayo Clin Proc,2003,78:15-17. 被引量:1
  • 8Manochakian R,Miller KC,Chanan-Khan AA.Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.Oncologist,2007,12:978-990. 被引量:1
  • 9Lee SJ,Richardson PG,Sonneveld P,et al.Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma:results from the APEX study.Br J Haematol,2008,143:511-519. 被引量:1

同被引文献98

引证文献12

二级引证文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部